Almukhadeb E, Almudimeegh A, Nagshabandi KN, Alsuwailem YL, Shadid A. The Efficacy and Safety of Biosimilars in Hidradenitis Suppurativa: A Comprehensive Review.
Clin Cosmet Investig Dermatol 2024;
17:1841-1851. [PMID:
39155882 PMCID:
PMC11328864 DOI:
10.2147/ccid.s478840]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2024] [Accepted: 08/05/2024] [Indexed: 08/20/2024]
Abstract
Hidradenitis Suppurativa (HS), also known as Acne Inversa, is a chronic, recurrent inflammatory skin condition primarily affecting apocrine gland-bearing areas, such as the axilla and groin. Characterized by painful nodules, abscesses, and scarring, and has a profound psychological impact on patients. Current treatments aim to manage symptoms and prevent new lesions with a combination of non-pharmacological and pharmacological approaches. Emerging biosimilars, which replicate the efficacy and safety profiles of known biologics at a lower cost, offer new options for treating this debilitating cutaneous disorder. The review summarizes recent studies to explain the role of biosimilars in HS, emphasizing their potential to expand effective treatment options.
Collapse